Gaucher disease type 3

Doctors may first notice a large spleen or liver, or low blood counts. The key test measures the enzyme glucocerebrosidase in white blood cells from a blood sample. Very low activity points to Gaucher disease. Genetic testing then looks for changes in both copies of the GBA1 gene. A blood marker called lyso-Gb1 (glucosylsphingosine) helps confirm the diagnosis and track treatment.

Telling type 3 apart from type 1 depends on the brain and nerves. A careful eye exam is the main clue. Almost everyone with type 3 has slow side-to-side eye jumps (horizontal saccades), the quick movements the eyes make when looking from one thing to another. Gene results can help too. Two copies of the L444P change (also written L483P) are most often linked to type 3. The N370S change (also written N409S) is not seen in the forms that affect the brain. But more than 500 changes are known, so the gene result often cannot predict the type.

The type can be hard to name in a very young child. Some people first thought to have type 1 are later found to have type 3. Diagnosis can take a long time: about 1 in 6 people with any type of Gaucher disease wait 7 years or more after first seeing a doctor with symptoms. Gaucher disease is not on the national U.S. newborn screening list. As of a 2025 report, six states screened all babies for it: Illinois, Missouri, New Jersey, Tennessee, Oregon and New Mexico.

Enzyme replacement therapy gives a lab-made version of the missing enzyme through a vein on a regular schedule, often every two weeks, long term. Imiglucerase (Cerezyme) is approved in the European Union and, since a January 2026 label update, in the United States to treat the non-brain problems of type 1 and type 3. It can shrink the spleen and liver and improve blood counts.

The enzyme cannot cross from the blood into the brain, so it does not treat the brain and nerve problems. Those are managed by specialists with seizure medicines, therapy, eye checks and school support. Researchers are studying newer treatments aimed at the brain. One is venglustat, a pill that was compared with enzyme therapy in a phase 3 trial of 43 people with type 3 aged 12 and older. As of September 2026 it was not approved in the United States. Gene therapy is also being studied.

Before enzyme therapy, a donor stem cell transplant was used to replace the patient’s macrophages with healthy donor cells. In wealthier countries, enzyme therapy replaced transplant in the 1990s because transplant carried high risks. A 2022 report followed nine patients transplanted in the UK and Sweden in the 1970s and 1980s for more than 20 years. Their blood counts were corrected, and none who kept the donor cells later needed enzyme therapy, but their brain and nerve problems kept progressing.

Some specialists suggest transplant may still have a place for selected children, especially where costly lifelong enzyme therapy cannot be guaranteed. In a 2023 report from Thailand, four children with type 3 had enzyme therapy and then a transplant. None had seizures or new nerve problems afterward, but they had varying degrees of learning and thinking difficulty. Transplant risks include infection, graft-versus-host disease and death.

Type 3 varies widely from person to person. Some people mainly have slow eye movements along with the body-wide problems. Others develop seizures, muscle jerks, balance problems or learning difficulties. Thinking skills range from severely affected to college graduates. The gene changes and the problems seen in childhood give useful clues about how it may go, but they cannot predict one person's future.

A standard reference describes survival into the 20s or 30s. Enzyme therapy now controls the blood, spleen and liver problems for many people, and specialists report that it improves quality of life and helps people live longer. In a 2025 study in England, living patients ranged from 6 to 61 years old. The brain and nerve problems shape the long-term outlook most, because enzyme therapy does not reach the brain. As of September 2026, a medicine designed to reach the brain, venglustat, was being tested for type 3 but was not approved in the United States.